



(86) Date de dépôt PCT/PCT Filing Date: 2004/02/18
 (87) Date publication PCT/PCT Publication Date: 2004/09/02
 (45) Date de délivrance/Issue Date: 2013/04/09
 (85) Entrée phase nationale/National Entry: 2005/08/18
 (86) N° demande PCT/PCT Application No.: US 2004/004646
 (87) N° publication PCT/PCT Publication No.: 2004/074444
 (30) Priorités/Priorities: 2003/02/19 (US60/447,690);
 2003/04/15 (US60/462,684)

(51) Cl.Int./Int.Cl. *C07F 15/02* (2006.01),
A01N 37/00 (2006.01)
 (72) Inventeurs/Inventors:
 KWOK, DAVID W. K., CA;
 STOYNOV, NIKOLAY MINTCHEV, CA
 (73) Propriétaire/Owner:
 GLOBOASIA LLC, US
 (74) Agent: MACPHERSON LESLIE & TYERMAN LLP

(54) Titre : COMPOSES ORGANIQUES FERRIQUES, UTILISATIONS DESDITS COMPOSES ET PROCEDES DE
 FABRICATION ASSOCIES
 (54) Title: FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME

(57) **Abrégé/Abstract:**

The present invention is directed to forms of ferric organic compounds, uses thereof, and methods of making same. The present invention discloses a novel physical form of ferric citrate with dissolution properties desirable for use in medicine, including the treatment of hyperphosphatemia and metabolic acidosis.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/074444 A3

(51) International Patent Classification⁷: **C07F 15/02,**
A01N 37/00

GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2004/004646

Declarations under Rule 4.17:

(22) International Filing Date: 18 February 2004 (18.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/447,690 19 February 2003 (19.02.2003) US
60/462,684 15 April 2003 (15.04.2003) US

(71) Applicant (for all designated States except US):
GLOBOASIA LLC [US/US]; 11427 Potomac Oaks
Drive, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KWOK, David,**
W., K. [CA/CA]; 4525 Wallace Street, Vancouver, British
Columbia V6S 2J6 (CA). **STOYNOV, Nikolay Mintchev**
[BG/CA]; 308-1749 Robson Street, Vancouver, British
Columbia V6G 1E1 (CA).

(74) Agents: **CHAN, Albert, Wai-Kit** et al.; Law Offices of
Albert Wai-Kit Chan, LLC, World Plaza, Suite 604, 141-07
20th Avenue, Whitestone, NY 11357 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,
LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG)

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,
BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

(88) Date of publication of the international search report:
14 April 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME

(57) Abstract: The present invention is directed to forms of ferric organic compounds, uses thereof, and methods of making same. The present invention discloses a novel physical form of ferric citrate with dissolution properties desirable for use in medicine, including the treatment of hyperphosphatemia and metabolic acidosis.

WO 2004/074444 A3

FERRIC ORGANIC COMPOUNDS, USES THEREOF AND
METHODS OF MAKING SAME

5

10

TECHNICAL FIELD

This invention relates to ferric organic compounds, methods of making the ferric organic compounds, and uses of the ferric organic compounds in the treatment of various disorders.

20

BACKGROUND OF THE INVENTION

25

1) Uses of Iron Compounds

Ferric iron containing compounds are useful in the treatment of a number of disorders, including, but not limited to, hyperphosphatemia and metabolic acidosis. Previous studies and inventions have reported the use of ferric compounds in binding with dietary phosphates, and such ferric compounds are potentially useful for the treatment of hyperphosphatemia in renal failure patients (U.S. Patent No. 5,753,706, 1998; CN 1315174, 2001; Yang W.C., et al., Nephrol. Dial. Transplant 17:265:270 (2002)). Elevated

amounts of phosphate in the blood can be removed by administering compounds such as ferric citrate. Once in solution, the ferric iron binds phosphate, and the ferric phosphate compounds precipitate in the gastrointestinal tract, resulting in effective removal of dietary phosphate from the body. It is also believed that the absorbed citrate from ferric citrate is converted to bicarbonate which corrects metabolic acidosis, a condition common in renal failure patients.

10

U.S. Patent No. 5,753,706 discloses the use of ferric containing compounds including ferric citrate and ferric acetate in the crystalline form, in an orally effective 1 gram dosage form, to bind to soluble dietary phosphate, causing precipitation of phosphate as ferric or ferrous phosphates in the gastrointestinal tract thus preventing oral absorption of soluble phosphates from dietary sources. Since the binding of ferric ions to soluble phosphate in the gastrointestinal tract would require dissolution of the orally administered ferric citrate, and since the rate of dissolution of crystalline ferric citrate is slow (over 10-12 hours at 37°C), oral administration of a substantially large dose of 1 g of ferric citrate is required. A related Chinese patent application (CN 1315174) also discloses a similar use of ferric citrate and related compounds in an oral solution dosage form for the treatment of hyperphosphatemia in renal failure patients.

30

2) Solution Chemistry of Fe(III) Compounds

Fe(III) is a lewis acid and is chemically less soluble in the stomach at pH normally below 5 than at intestinal pH

normally above 7. The stomach is believed to be an important site of action for the dissolution of Fe(III) compounds. It is also believed that the stomach is also an important site of action for Fe(III) to mediate its action in binding to dietary phosphates, preventing phosphate from reaching the intestine and thus reducing the absorption of phosphates from the intestine.

SUMMARY OF THE INVENTION

In accordance with these and other objects of the invention, a brief summary of the present invention is presented. Some
5 simplifications and omission may be made in the following summary, which is intended to highlight and introduce some aspects of the present invention, but not to limit its scope. Detailed descriptions of a preferred exemplary embodiment adequate to allow those of ordinary skill in the art to make
10 and use the invention concepts will follow in later sections.

This invention relates to novel forms of ferric organic compounds, methods of making these compounds, and uses of these compounds in the treatment of various disorders,
15 including, but not limited to, hyperphosphatemia and metabolic acidosis.

The novel forms of ferric organic compounds are synthesized by adding an alkaline metal hydroxide to a water soluble
20 ferric iron salt. The alkaline metal hydroxide can comprise sodium hydroxide, potassium hydroxide, or any other suitable alkaline metal hydroxide. The soluble ferric iron salt can comprise ferric chloride hexahydrate, or any other suitable ferric iron salt. The alkaline metal hydroxide is added at
25 a specific rate and temperature to form a uniform polyiron oxo colloidal suspension. The colloidal suspension is then washed, and solid crystalline organic acid is added at a specific temperature to form the ferric organic compound in solution. The organic acid can comprise citric acid,
30 acetic acid, isocitric acid, succinic acid, fumaric acid, tartaric acid, or any other suitable organic acid. The novel forms of the ferric organic compounds are precipitated out of solution using an organic solvent. The organic solvent

can comprise ethanol, methanol, butanol, acetone, isopropyl alcohol, tetrahydrofuran, or any other suitable organic solvent. The resulting novel forms of the ferric organic compounds have an enhanced dissolution rate.

5 In one embodiment, the novel form of ferric organic compound comprises a novel form of ferric citrate. The novel form of ferric citrate is synthesized by adding sodium hydroxide at a specific rate and temperature to ferric chloride
10 hexahydrate to form a uniform colloidal suspension of ferric hydroxide. Solid crystalline citric acid is added to the colloidal suspension and heated to a specific temperature range to form ferric citrate in solution. The novel form of ferric citrate is precipitated out of solution using an
15 organic solvent.

The novel form of ferric citrate has the formula $C_6H_5O_7Fe$ and has novel physical properties as determined by dissolution rates. The compound can have an intrinsic dissolution rate
20 range, as determined by USP intrinsic dissolution assay in water, between 1.9 to 4.0 mg/cm²/min. The novel form of ferric citrate is more aqueously soluble in a wider range of pH than commercially available forms of ferric citrate. The novel form of ferric citrate can have a large active surface
25 area compared to commercially available forms of ferric organic compounds or complexes.

Because it is more soluble, the novel form of ferric organic compounds, including novel forms of ferric citrate, can be
30 used to more effectively deliver ferric organic compounds by the route of oral administration to patients suffering from illnesses which are responsive to treatment with ferric

organic compounds, including, but not limited to, hyperphosphatemia and metabolic acidosis.

This invention relates to use of the novel form of ferric
5 organic compounds, including novel forms of ferric citrate
to treat patients suffering from disorders responsive to
ferric organic compound treatment.

This invention also relates to methods of treating patients
10 suffering from disorders responsive to ferric organic
compound treatment by administering a therapeutically
effective amount of ferric organic compound to the patients.

DETAILED DESCRIPTION OF THE FIGURES

In drawings which illustrate specific embodiments of the invention, but which should not be construed as restricting
5 the spirit or scope of the invention in any way:

Figure 1 is a schematic diagram outlining the method of making novel forms of ferric organic compounds according to the invention.

10

Figure 2 is a plot of the dissolution profile of the novel form of ferric citrate of the invention compared to a commercially available compound.

15

Figure 3 is an isotherm graph of volume adsorbed vs. relative pressure demonstrating BET active surface area of the novel form of ferric citrate. Produced by Coulter SA 3100 (Serial No. z11017; Software Version 2.13; Elapsed time: 29 min.; Outgas time: 60 min.; Outgas temperature: 40°C)

20

Figure 4 is an X-ray diffraction spectra of the novel form of ferric citrate. Range: 4.00 to 40.00 (Deg); Step Scan Rate: 0.02 Deg/min.

25

Figure 5 is a thermogravimetric analysis of the novel form of ferric citrate. Method: Heating 10°C/MIN, N2@40CC/MIN; Size: 10.5480 mg.

DETAILED DESCRIPTION OF THE INVENTION

Throughout the following description, specific details are set forth in order to provide a more thorough understanding of the invention. However, the invention may be practiced without these particulars. In other instances, well known elements have not been shown or described in detail to avoid unnecessarily obscuring the invention. Accordingly, the specification and drawings are to be regarded in an illustrative, rather than a restrictive, sense.

This invention provides a method of synthesizing a form of ferric organic compound which comprises obtaining a ferric iron salt; adding an alkaline metal hydroxide to the ferric iron salt at a rate and temperature effective to produce a uniform polyiron oxo suspension; isolating a precipitate from the suspension; adding an organic acid to the precipitate; forming a ferric-organic acid solution by heating the organic acid and the precipitate; and precipitating the form of ferric organic compound from the ferric-organic acid solution by adding an organic solvent to the solution.

In an embodiment, the alkaline metal hydroxide is added at a rate of less than 20 ml/min. In another embodiment, the alkaline metal hydroxide is added at a rate of between about 10 ml/min and about 20 ml/min. In a preferred embodiment, a nominal rate of 10 to 20 ml/min is preferred.

In an embodiment, the alkaline metal hydroxide is added to the ferric iron salt at a temperature of less than 40°C. In another embodiment, the alkaline metal hydroxide is added to the ferric iron salt at a temperature between about 10°C and

about 40°C. In a preferred embodiment, a nominal temperature of 30°C is preferred.

In an embodiment, heating the organic acid and the precipitate comprises heating the organic acid and the precipitate to a temperature between about 75°C to about 95°C. In a preferred embodiment, the range is between about 80°C and about 90°C. In another preferred embodiment, a nominal temperature of 85°C is preferred. In an embodiment, precipitating the form of ferric organic compound from the ferric-organic acid solution by adding an organic solvent to the solution comprises cooling the ferric-organic acid solution to less than 30°C before adding the organic solvent. In a preferred embodiment, the ferric-organic acid solution is cooled to a nominal temperature of 20°C. In an embodiment, cooling the ferric-organic acid solution comprises cooling the ferric-organic acid solution to a temperature between about 10°C and about 30°C. In a preferred embodiment, the ferric-organic acid solution is cooled to a nominal temperature of 20°C.

In an embodiment, the ferric iron salt comprises ferric chloride hexahydrate.

In an embodiment, the organic acid includes but is not limited to succinic acid, fumaric acid or tartaric acid. In another embodiment, the organic acid comprises citric acid.

In an embodiment, the alkaline metal hydroxide includes but is not limited to sodium hydroxide or potassium hydroxide. In another embodiment, the alkaline metal hydroxide comprises sodium hydroxide.

In an embodiment, the organic solvent includes but is not limited to ethanol, methanol, butanol, isopropyl alcohol, acetone or tetrahydrofuran.

5 This invention provides a method of synthesizing a form of ferric citrate which comprises obtaining ferric chloride hexahydrate; adding sodium hydroxide to the ferric chloride hexahydrate at a rate and temperature effective to produce a uniform polyiron oxo suspension; isolating a precipitate
10 from the suspension; adding crystalline citric acid to the precipitate; forming a ferric-citric acid solution by heating the citric acid and the precipitate; and precipitating the form of ferric citrate from the ferric-citric acid solution by adding an organic solvent to the
15 solution.

In an embodiment, sodium hydroxide is added to ferric chloride hexahydrate at a rate of less than 20 ml/min. In another embodiment, sodium hydroxide is added to ferric
20 chloride hexahydrate at a rate of between about 10 ml/min and about 20 ml/min. In a preferred embodiment, a nominal rate of 10 to 20 ml/min is preferred.

In an embodiment, sodium hydroxide is added to ferric
25 chloride hexahydrate at a temperature of less than 40°C. In another embodiment, sodium hydroxide is added to ferric chloride hexahydrate at a temperature between about 10°C and about 40°C. In a preferred embodiment, a nominal temperature of 30°C is preferred.

30 In an embodiment, the ferric-citric acid solution is formed by heating the citric acid and the precipitate to a temperature between about 75°C to about 95°C. In a preferred

embodiment, the range is between about 80°C and about 90°C. In another preferred embodiment, a nominal temperature of 85°C is preferred.

5 In an embodiment, precipitating the form of ferric citrate from the ferric-citric acid solution by adding an organic solvent to the solution comprises cooling the ferric-citric acid solution to less than 30°C before adding the organic solvent. In a preferred embodiment, the ferric-organic acid
10 solution is cooled to a nominal temperature of 20°C.

In an embodiment, cooling the ferric-citric acid solution comprises cooling the ferric-citric acid solution to a temperature between about 10°C and about 30 °C. In a
15 preferred embodiment, the ferric-organic acid solution is cooled to a nominal temperature of 20°C.

In an embodiment, the organic solvent includes but is not limited to ethanol, methanol, butanol, isopropyl alcohol,
20 acetone or tetrahydrofuran.

This invention provides a use of a form of ferric organic compound or ferric citrate as describe above for treating a person suffering from a disorder responsive to ferric
25 organic compound therapy. In an embodiment, the disorder includes but is not limited to hyperphosphatemia or metabolic acidosis.

This invention provides a method of treating a person
30 suffering from a disorder responsive to ferric organic compound therapy comprising administering to the person a therapeutically effective amount of an ferric organic compound as described above. In an embodiment, the ferric

organic compound is ferric citrate. In another embodiment, the disorder includes but is not limited to hyperphosphatemia or metabolic acidosis.

5 This invention provides a form of a ferric organic compound having an enhanced dissolution rate. In an embodiment, the said organic compound includes but is not limited to citric acid, acetic acid, isocitric acid, succinic acid, fumaric acid, tartaric acid or other related organic compounds. In
10 another embodiment, the said ferric organic compound has a large active surface area compared to conventional ferric organic compounds.

This invention provides a form of ferric citrate having the
15 formula $C_6H_5O_7Fe$ and/or having physical properties as determined by dissolution rates. In an embodiment, the dissolution rate, as determined by USP intrinsic dissolution assay in water, is between 1.9 to 4.0 mg/cm²/min.

20 This invention provides a form of ferric citrate having a BET active surface area exceeding 16 sq.m/g and a BET active surface area isotherm as shown in Figure 3.

This invention provides a form of ferric citrate having the
25 x-ray diffraction pattern shown in Figure 4.

This invention provides a form of ferric citrate having three transition temperatures as determined by thermogravimetric analysis (TGA) and having a TGA profile as
30 shown in Figure 5.

This invention provides a form of ferric citrate, wherein the form of ferric citrate has a large active surface area compared to conventional ferric organic compound complexes.

This invention provides a use of a form of ferric organic compound or ferric citrate to treat a person suffering from a disorder responsive to ferric organic compound therapy. In
5 an embodiment, the disorder includes but is not limited to hyperphosphatemia or metabolic acidosis.

This invention provides a method of treating a person suffering from a disorder responsive to ferric organic
10 compound therapy comprising administering to the person a therapeutically effective amount of a form of ferric organic compound or ferric citrate as described above. In an embodiment, the disorder includes but is not limited to hyperphosphatemia or metabolic acidosis.

15 This invention provides a form of ferric organic compound or ferric citrate as describe above, wherein said form of ferric organic compound or ferric citrate is in an orally administrable form which includes but is not limited to a
20 powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a liquid, a spirit or a syrup. In an embodiment, the ferric organic compound or ferric citrate is in a form or in an acceptable carrier suitable for topical, sublingual, parenteral or gastrointestinal administration,
25 or aerosolization.

This invention provides a composition comprising a form of ferric organic compound or ferric citrate as describe above and a suitable carrier.

30 As used herein, the term suitable carrier includes but not limited to any suitable carrier for administering pharmaceutical compositions known to those of ordinary skill

in the art. The type of carrier will vary depending on the mode of administration.

5 With regards to compositions for parenteral administration (e.g. subcutaneous injections), the term suitable carrier includes but not limited to water, saline, alcohol, a fat, a wax or a buffer.

10 With regards to compositions for oral administration, the term suitable carrier includes but not limited to any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed.

15 Biodegradable microspheres (e.g., polylactate polyglycolate) may also be employed as carriers for the pharmaceutical compositions of this invention.

20 This invention provides a pharmaceutical composition comprising a form of ferric organic compound or ferric citrate as describe above and a pharmaceutically acceptable carrier. In another embodiment, the pharmaceutically acceptable carrier comprises a controlled release
25 formulation.

This invention provides a pharmaceutical composition comprising an effective amount of a form of ferric organic compound or ferric citrate as describe above for treating
30 disorders responsive to ferric organic compound therapy. In an embodiment, the disorder includes but is not limited to hyperphosphatemia and metabolic acidosis.

As used herein, pharmaceutically acceptable carriers includes but is not limited to a liquid, an aerosol, a capsule, a tablet, a pill, a powder, a gel, an ointment, a cream, a granule, water, phosphate buffered saline, Ringer's
5 solution, dextrose solution, serum-containing solutions, Hank's solution, other aqueous physiologically balanced solutions, oils, esters, glycols, biocompatible polymers, polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices,
10 liposomes, lipospheres, cells or cellular membranes.

1. General Method of Synthesis of Novel Forms of Ferric Organic Compounds

Referring to Figure 1, synthesis scheme 10 is a general
5 method for synthesizing novel forms of ferric organic
compounds. The starting materials, as indicated in box 20,
comprise soluble ferric iron salts. The soluble ferric iron
salts can comprise ferric chloride hexahydrate ($\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$),
as indicated in box 21, or any other suitable soluble ferric
10 iron salt. Next, an alkaline metal hydroxide (box 30) is
added at a specific rate and temperature to the soluble
ferric iron salt. The addition of the alkaline metal
hydroxide at a specific rate (preferably between about 10
ml/min and about 20 ml/min) and temperature range
15 (preferably below 40°C) results in the formation of a
uniform polyiron oxo colloidal suspension. The alkaline
metal hydroxide can comprise sodium hydroxide, potassium
hydroxide, or any other suitable alkaline metal hydroxide as
indicated in box 31. The colloidal suspension precipitate
20 is collected and rinsed (box 40) with distilled water to
remove any soluble impurities. After rinsing, the
precipitate is re-suspended and, as indicated in box 50,
crystalline organic acid is added to the precipitate and
heated to a particular temperature range (preferably between
25 about 80°C to about 90°C). The organic acid can comprise
any suitable organic acid. Box 51 lists some of the
possible organic acids which can be used, including, but not
limited to, citric acid, acetic acid, isocitric acid,
succinic acid, fumaric acid, and tartaric acid. The
30 addition of the organic acid allows the acid to form
complexes with the precipitate in solution. At box 60, the
ferric organic compound is precipitated out of solution with
an organic solvent to form a novel form of ferric organic

compound (box 70). Various organic solvents can be used, including, but not limited to, the solvents described in box 61, such as ethanol, methanol, butanol, acetone, isopropyl alcohol, tetrahydrofuran, or any other suitable organic solvent.

2. Solubility Profile of Novel Forms of Ferric Organic Compounds

The inventors have found that the novel forms of ferric organic compounds produced according to the methods described above are more soluble than commercially available ferric organic compounds, over a wider range of pH levels. This increase in solubility of the novel ferric organic compounds is believed to be a result of the unique significantly large active surface area of the novel forms of ferric organic compounds.

3. Use of Novel Forms of Ferric Organic Compounds in the Treatment of Disorders

The novel forms of ferric organic compounds are useful in the treatment of hyperphosphatemia, metabolic acidosis, and any other disorders responsive to ferric organic compound therapy. Because the novel forms of ferric organic compounds are more soluble than commercially available ferric organic compounds, smaller amounts of the ferric organic compounds can be used to effectively treat patients suffering from such disorders.

Improved aqueous solubility is particularly relevant to the use of the novel forms of ferric organic compounds in the treatment of disorders responsive to ferric organic compound therapy. Because the novel forms of ferric organic compounds are more soluble, they will be more effective when

taken orally, and therefore can be taken in lower doses. The novel forms of ferric organic compounds are more soluble over a wider pH range than commercially available ferric organic compounds, therefore the novel forms of ferric organic compounds can be more effective by being soluble in the small intestine. As a result, patients can take lower doses of medication with lower incidences of side effects.

In one embodiment of the invention, the novel form of ferric citrate has a significantly higher rate of aqueous solubility under physiological conditions than commercially available forms of ferric citrate; and therefore the novel form is believed to provide a significant improvement in the orally effective use of ferric citrate at a reduced dosage. By reducing the orally effective dose of ferric citrate, it is believed that the novel form of ferric citrate will provide a lower incidence of ulcerative gastrointestinal adverse effects associated with commercially available ferric citrate compounds. In addition, it is believed that the increased rate of dissolution of the novel form of ferric citrate will provide a more rapid onset of action in binding to dietary phosphate.

The novel forms of ferric organic compounds can be administered in a number of forms, including orally administrable forms, which can comprise the novel forms of ferric organic compounds alone or in combination with a pharmaceutically acceptable carrier. The orally administrable form can be selected from the group consisting of a tablet, a powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a liquid, a spirit, and a syrup. The composition can be administered to human beings or other

animals suffering from illnesses responsive to ferric organic compound therapy.

Examples

5

In examples which are intended to illustrate embodiments of the invention but which are not intended to limit the scope of the invention:

10 *1) Method of Making A Novel Form of Ferric Citrate*

In one embodiment of the invention, the starting materials for making a novel form of ferric citrate comprise a 1.85M solution of ferric chloride hexahydrate ($\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$). A
15 volume of 5M sodium hydroxide necessary to produce a 1:3 ratio of ferric iron to hydroxide ion is added to the ferric chloride hexahydrate solution at a rate of less than 20 ml per minute, preferably between about 10 ml per minute and about 20 ml per minute. The temperature of the mixture is
20 maintained below 40°C , preferably between about 10°C to about 40°C , while the sodium hydroxide is added to form a polyiron oxide colloidal suspension of ferric hydroxide. The pH of the suspension is measured while the sodium hydroxide is added. Once the pH is above 7.0, the suspension is cooled
25 until it is less than 30°C , preferably between about 10°C to about 30°C . The suspension is then filtered through a 1 mm pore filter to breakup aggregates and remove large particles of ferric hydroxide precipitate. The filtered ferric hydroxide suspension is then centrifuged. The supernatant
30 is discarded, then the precipitated ferric hydroxide is centrifuged again to remove any remaining supernatant. The ferric hydroxide precipitate is then resuspended with distilled water. The centrifugation-resuspension steps are repeated two more times to wash the ferric hydroxide

precipitate and remove water soluble impurities. The resulting ferric hydroxide precipitate is then homogenized.

An amount of citric acid necessary to produce a 1:1 ratio of ferric iron to citrate is added to the precipitate. The mixture is heated to between about 80°C to about 90°C in an oil bath until the color of the mixture changes from orange-brown to a clear black-brown, or until all of the ferric hydroxide precipitate is dissolved. The reaction is cooled until it is less than 30°C, preferably between about 10°C to about 30°C, and the pH is measured to determine that it is within 0.8 and 1.5. The reaction is centrifuged, and the supernatant is collected.


The novel form of ferric citrate is precipitated from the supernatant by adding 5 volumes of organic solvent. Various organic solvents can be used, including ethanol, methanol, butanol, acetone, isopropyl alcohol, or tetrahydrofuran. Table 1 below lists the relative amounts of ferric citrate formed in solution using various solvents. Once the solvent is added, the mixture is stirred until a light beige precipitate forms. The suspension is centrifuged and the supernatant is discarded. The precipitate is washed and centrifuged with the solvent two more times. The precipitate is then dried in a vacuum oven for 8 to 16 hours at ambient temperature or by any other suitable industrial processes such as fluidized-bed drying. The dried precipitate is ground with a mortar and pestle and dried for another 8 to 24 hours at ambient temperature. The fine precipitate is finely ground by milling again and screened through a 45 mesh size (35 micron) sieve. The novel form of ferric citrate powder is dried in the vacuum oven again or

fluidized-bed drying again and dried at ambient temperature until 1 hour of drying leads to less than 0.25% loss in weight.

5 **Table 1. Comparison of relative percentage of novel form of ferric citrate formed by different organic solvents**

Solvent	Relative % of Novel Form of Ferric Citrate Formed in Solution
ferric citrate	100
isopropyl alcohol	89.7
tetrahydrofuran	90.6
butanol	99.8
methanol	101.2
acetone	99.8
ethanol	95.8

10 The following chemical equations represent the chemical reactions described in the specific embodiment of the method for making the novel form of ferric citrate:



20 *2) Physical Properties of Novel Form of Ferric Citrate*

The chemical purity of the novel form of ferric citrate was ascertained by negative-ion liquid chromatography / mass spectrometry (LC/MS) flow-injection method which provided measurement of all mass ions present in solution. Specifically, the mass ions at m/z 243.6 for the novel form of ferric citrate and at m/z 190.6 for citric acid amongst other related and non-related ions in solution were observed. The use of LC/MS analysis also enabled the observation of a number of ferric citrate related and non-related substances and permitted the determination of the relative purity of

30

the novel form of ferric citrate amongst the minor impurities. Such information is critical for application of the novel form of ferric citrate as pharmaceutical grade material. The representative chemical purity of the novel form of ferric citrate from three process batches are presented in Table 2.

Table 2. Representative chemical purity of novel form of ferric citrate

Components of Novel form of Ferric citrate	Percent w/w anhydrous basis		
Purity of solid state ferric citrate	99.4 %	99.6 %	99.5 %
Assay content purity of ferric citrate and ferric citrate water adduct in solution state	73.1 %	78.3 %	76.2 %
Assay content of citric acid in solution state	10.3 %	10.0 %	8.0 %
Assay content of ferric citrate related substances in solution state	26.3%	21.3%	23.3%
Assay content of ferric citrate non-related substances in solution state	0.6%	0.4%	0.5%

The intrinsic dissolution rates of commercially available ferric citrate were compared with the novel form of ferric citrate. The intrinsic dissolution rate is defined as the dissolution rate of pure substances under the condition of constant surface area. The dissolution rate and bioavailability of a drug substance is influence by its solid state properties: crystallinity, amorphism, polymorphism, hydration, solvation, particle size and particle surface area. The measured intrinsic dissolution rate is dependent on these solid-state properties and is

typically determined by exposing a constant surface area of a material to an appropriate dissolution medium while maintaining constant temperature, stirring rate, and pH. The intrinsic dissolution rates are presented in Table 3.

5

Table 3. Intrinsic dissolution rates of ferric citrate at 37 /C in solutions of pH 8

Sample	Rate of Acetone Addition (ml/min)	Intrinsic Dissolution Rates (mg/cm ² /min)	Mean Intrinsic Dissolution Rates (mg/cm ² /min)
RFS-12 (sigma / commercially available)	10.0	0.83	0.83
STM-134 (reference material)	10.0	1.88	3.08
PAN031203A (experimental batch 1)	10.0	3.82	
PAN031203B (experimental batch 2)	10.0	4.00	
PAN031203C (experimental batch 3)	9.5	2.68	
PAN031203D (experimental batch 4)	40	2.95	
PAN031203E (experimental batch 5)	4.4	3.13	

10

Figure 2 is a graph which compares the dissolution profile of the novel form of ferric citrate to the dissolution profile of commercially available ferric citrate compounds.

15

The intrinsic dissolution rates of the novel form of ferric citrate produced by the method of the invention, on average,

are approximately 3.8 times greater than that determined for a commercially available ferric citrate material. This increase in dissolution rate of the novel form of ferric citrate is believed to be a result of the significantly large active surface area of the novel form of ferric citrate compared to commercially available materials.

A BET active surface area isotherm of the novel form of ferric citrate is shown in Figure 3. The analysis of active surface area is based on BET theory which describe the phenomenon of mass and energy interaction and phase changes during gas adsorption onto solid surfaces and in pore spaces. In BET active surface area measurement, the volume of a monolayer of gas is determined which allows the surface area of the sample to be determined using the area occupied by a single layer of adsorbed gas molecule. Table 4 is a comparison of the active surface area of the novel form of ferric citrate compared to the active surface area of commercially available ferric citrate compounds.

Table 4. BET active surface areas of various forms of ferric citrate

Sample	Mean Dissolution Rates (mg/cm ² /min)	BET Active Surface Area
RFS-12-1 (sigma / commercially available)	0.76	0.61
RFS-12-2 (sigma / commercially available)		
STM-134-1 (reference material 1)	2.47	16.17
STM-134-2 (reference material 2)		
STM-182-1 (lab-scale 500 g batch 1)	2.61	19.85
STM-182-2 (lab-scale 500 g batch 2)		

5

The x-ray diffraction spectra of the novel form of ferric citrate is presented in Figure 4, showing diffraction features characteristics of crystalline materials. The thermogravimetric analysis of the novel form of ferric citrate is presented in Figure 5, showing heat absorption isotherms characteristics of the novel material.

As will be apparent to those skilled in the art in the light of the foregoing disclosure, many alterations and modifications are possible in the practice of this invention without departing from the spirit or scope thereof. Accordingly, the scope of the invention is to be construed in accordance with the substance defined by the following claims.

20

What is claimed is:

1. A method of synthesizing a ferric organic compound comprising:
 - a) adding a metal hydroxide to a ferric iron salt at a rate and temperature effective to produce a polyiron oxo suspension;
 - b) washing the suspension;
 - c) adding crystalline organic acid to the suspension and heating to between 75°C and 95°C; and
 - d) adding an organic solvent to precipitate the ferric organic compound.
2. The method of claim 1, wherein the washing comprises isolating a precipitate from the suspension and washing the precipitate.
3. The method of claim 1, wherein the metal hydroxide is added at a rate of less than 20 ml/min.
4. The method of claim 3, wherein the rate is between about 10 ml/min and about 20 ml/min.
5. The method of any one of claims 1 to 4, wherein the metal hydroxide is added to the ferric iron salt at a temperature of less than 40°C.
6. The method of claim 5, wherein the temperature is between about 10°C and about 40°C.


7. The method of any one of claims 1 to 6, wherein step d) comprises cooling the suspension to less than 30°C before adding the organic solvent.
8. The method of any one of claims 1 to 6, wherein step d) comprises cooling the suspension to a temperature between about 10°C and about 30°C.
9. The method of any one of claims 1 to 8, wherein the ferric iron salt comprises ferric chloride hexahydrate.
10. The method of any one of claims 1 to 9, wherein the organic acid is selected from the group consisting of citric acid, acetic acid, isocitric acid, succinic acid, fumaric acid, and tartaric acid.
11. The method of claim 9, wherein the organic acid comprises citric acid.
12. The method of any one of claims 1 to 11, wherein the metal hydroxide is selected from the group consisting of sodium hydroxide and potassium hydroxide.
13. The method of claim 12, wherein the metal hydroxide is sodium hydroxide.
14. The method of any one of claims 1 to 13, wherein the organic solvent is selected from the group consisting of ethanol, methanol, butanol, isopropyl alcohol, acetone, and tetrahydrofuran.

15. A method of synthesizing ferric citrate comprising:
 - a) adding sodium hydroxide to ferric chloride hexahydrate at a rate and temperature effective to produce a polyiron oxo suspension;
 - b) adding crystalline citric acid to the suspension and heating to between 75°C and 95°C; and
 - c) adding an organic solvent to precipitate the ferric citrate.
16. The method of claim 15, wherein sodium hydroxide is added to ferric chloride hexahydrate at a rate of less than 20 ml/min.
17. The method of claim 16, wherein the rate is between about 10 ml/min and about 20 ml/min.
18. The method of any one of claims 15 to 17, wherein sodium hydroxide is added to ferric chloride hexahydrate at a temperature of less than 40°C.
19. The method of any one of claims 15 to 17, wherein sodium hydroxide is added to ferric chloride hexahydrate at a temperature between about 10°C and about 40°C.
20. The method of any one of claims 15 to 19, wherein step c) comprises cooling the suspension to less than 30°C before adding the organic solvent.
21. The method of any one of claims 15 to 19, wherein step c) comprises cooling the suspension to a temperature between about 10°C and about 30°C.

22. The method of any one of claims 15 to 21, wherein the organic solvent is selected from the group consisting of ethanol, methanol, butanol, isopropyl alcohol, acetone, and tetrahydrofuran.
23. Solid ferric citrate having a BET active surface area exceeding $16 \text{ m}^2/\text{g}$.
24. Solid ferric citrate having a dissolution rate of between 1.88 and $4.0 \text{ mg}/\text{cm}^2/\text{min}$, as determined by USP intrinsic dissolution assay in water.
25. Use of the ferric citrate of claim 23 or 24 for the treatment of hyperphosphatemia.
26. Use of the ferric citrate of claim 23 or 24 for the treatment of metabolic acidosis.
27. A pharmaceutical composition comprising solid ferric citrate having a BET active surface area exceeding $16 \text{ m}^2/\text{g}$ and a pharmaceutically acceptable carrier.
28. A pharmaceutical composition comprising solid ferric citrate having a dissolution rate of between 1.88 and $4.0 \text{ mg}/\text{cm}^2/\text{min}$, as determined by USP intrinsic dissolution assay in water, and a pharmaceutically acceptable carrier.
29. The pharmaceutical composition of claim 27 or 28, which is formulated for oral administration.


30. The pharmaceutical composition of any one of claims 27-29, which is formulated as a tablet, powder, suspension, emulsion, capsule, granule, troche, pill, liquid, spirit, or syrup.
31. The pharmaceutical composition of any one of claims 27-30, which is formulated as a tablet.
32. Use of the pharmaceutical composition of any one of claims 27-31 for treating hyperphosphatemia.
33. Use of the pharmaceutical composition of any one of claims 27-31 for treating metabolic acidosis.
34. An orally administrable pill, comprising solid ferric citrate having a BET active surface area exceeding $16 \text{ m}^2/\text{g}$ and a suitable carrier.
35. An orally administrable pill, comprising solid ferric citrate having a dissolution rate of between 1.88 and 4.0 $\text{mg}/\text{cm}^2/\text{min}$, as determined by USP intrinsic dissolution assay in water, and a suitable carrier.
36. Use of the pill of claim 34 or 35 for treating hyperphosphatemia.
37. Use of the pill of claim 34 or 35 for treating metabolic acidosis.

Figure 1




2/5

Figure 2




3/5

Figure 3



4/5

Figure 4



5/5
Figure 5

